Lung cancer Drug's journey through the body tracked in tiny trial
NCT ID NCT07620951
First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 4 times
Summary
This early-stage study will give 8 healthy Chinese men a single dose of the experimental lung cancer drug zorifertinib, which has been tagged with a tiny amount of radioactivity. By collecting blood, urine, and stool samples over two weeks, researchers will track exactly how the drug is broken down and eliminated. The goal is not to test if it works against cancer, but to understand its metabolism and excretion to guide future dosing studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zorifertinib (radioactive-labelled)
- What this could lead to
- If successful, this study will show how zorifertinib is broken down and removed from the body, which helps design better dosing for future lung cancer patients.
- What could go wrong
- This is a very early, small study in just 8 healthy people, not patients. It only measures drug processing, not whether the drug works against cancer. Results may not predict effects in sick patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM (CNS) METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain metastases breakthrough? scientists probe how a powerful drug crosses into the brain
- New combo therapy aims to control advanced lung cancer
- New drug cocktail targets Hard-to-Treat lung cancer with liver metastases
- Experimental lung cancer drug trial halted early
- New drug zorifertinib aims to fight lung cancer in the brain